This is a single-arm phase 2 study in adults with Sickle Cell Disease (SCD) to assess the effect of oral isoquercetin on biomarkers of endothelial and platelet activation, inflammation and ongoing blood coagulation.~The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~The names of the study drug involved in this study are/is: Isoquercetin~Participants will receive study treatment for 1 year and will be followed for 30 days after the last dose.~This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. Investigational means that the drug is being studied.~The U.S. Food and Drug Administration (FDA) has not approved isoquercetin as a treatment for any disease.
This research study is being done to assess the safety and effectiveness of isoquercetin to reduce levels of soluble P-Selectin in patients with sickle cell disease. Isoquercetin is a naturally occurring flavonoid-or vitamin. You will find quercetin and isoquercetin in fruits and vegetables.~The names of the study drug involved in this study are/is:~- Isoquercetin